Although in silico analyses and preliminary experimental validation have shown potential oncogenic roles of DUXAP8 and DUXAP9 and its underlying ceRNA regulatory mechanism in renal cell carcinoma, much more experiments and big clinical trials need to be launched to further confirm these preliminary data in the future. The gene discussed is DUXAP9; the disease is hereditary clear cell renal cell carcinoma.